This Brinker International Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Mondaybenzinga_article·Aug 24 at 11:50 AMNVCT+3.30%AEVA+2.17%
Nuvectis Pharma sets up $200 million at-the-market equity program with JefferiesPUBT·Aug 21 at 08:31 PMNVCT+3.30%JEF+1.56%
Nuvectis Pharma (NASDAQ:NVCT) Shares Gap Up - What's Next?Market Beat·Aug 14 at 03:00 PMNVCT+3.30%JPM-0.03%
Nuvectis Pharma’s Heavy Reliance on Haisco Poses Major Operational and Geopolitical RisksTip Ranks·Aug 5 at 06:01 AMNVCT+3.30%
Nuvectis Pharma: Buy Rating Reiterated as Late-Stage Pipeline Expands and $39 Price Target Remains UnchangedTip Ranks·Aug 4 at 04:35 PMNVCT+3.30%
Nuvectis Pharma (NASDAQ:NVCT) Shares Gap Down After Earnings MissMarket Beat·Aug 4 at 02:20 PMNVCT+3.30%
Nuvectis Pharma Q2 FY26 net loss widens to USD 7.02 millionPUBT·Aug 4 at 12:08 PMNVCT+3.30%002653+0.41%
Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business HighlightsUnusual Whales·Aug 4 at 12:05 PMNVCT+3.30%
Pantginis Reiterates Buy on Nuvectis, Citing Ciprocopan Approval and Pipeline Diversification; Price Target Maintained at $39Tip Ranks·Jul 23 at 03:25 PMNVCT+3.30%
Nuvectis says China regulator approves ciprocopan for treatment-naive PNH patientsPUBT·Jul 23 at 11:32 AMNVCT+3.30%002653+0.41%
Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement InhibitorsUnusual Whales·Jul 23 at 11:33 AMNVCT+3.30%
